Appendix A: Guideline Development Groups & Declarations of Interest

A.1 Guideline development group members

A.1.1 Guideline development group for 2015

Damien Longson (Guideline Chair)
Consultant Liaison Psychiatrist, Manchester Mental Health and Social Care Trust

Amanda Adler
Consultant Diabetologist, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust

Anne Bentley
Medicines Optimisation Lead Pharmacist, NHS East Lancashire Primary Care Trust

Christine Bundy (co-opted expert member)
Senior Lecturer in Behavioural Medicine, Institute for Inflammation & Repair, University of Manchester

Bernard Clarke (co-opted expert member)
Honorary Clinical Professor of Cardiology, Manchester Academic Health Science Centre, University of Manchester

Maria Cowell
Community Diabetes Specialist Nurse, Cambridge

Indranil Dasgrupta (co-opted expert member)
Consultant Nephrologist, Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust

David Ronald Edwards (co-opted expert member)
Principal in General Practice, Whitehouse Surgery, Oxfordshire

Andrew Farmer
Professor in General Practice, Department of Primary Care Health Sciences, University of Oxford

Ian Lewin
Consultant Diabetologist, North Devon District Hospital, Northern Devon Healthcare NHS Trust

Natasha Jacques
Principal Pharmacist in Diabetes, Heart of England NHS Foundation Trust, Birmingham
Guideline Development Groups & Declarations of Interest

Yvonne Johns
Patient/carer member

Natasha Marsland
Patient/carer member, Diabetes UK

Prunella Neale
Practice Nurse, Herschel Medical Centre, Berkshire

Jonathan Roddick
Principal General Practitioner, Woodseats Medical Centre, Sheffield

Mohammed Roshan (August 2012 - October 2013)
Principal in General Practice, Leicester City and County

Sailesh Sankar
Consultant Diabetologist, University Hospitals Coventry and Warwickshire NHS Trust

A.1.2 Guideline development group for 2009 (NICE clinical guideline 87)

Amanda Adler (Chair)
Consultant Physician with an interest in diabetes, Addenbrooke’s Hospital, Cambridge

Claudette Allerdyce
Principal Locality Pharmacist, Croydon Primary Care Trust

Tony Doherty
Diabetes Nurse Specialist and Service Improvement Officer, Diabetes UK (Scotland)

Andrew Farmer
University Lecturer in General Practice, University of Oxford

Niru Goenka
Consultant Physician with an interest in diabetes/endocrinology, Countess of Chester NHS Foundation Trust

Martin Hadley-Brown
General Practitioner, Thetford, Norfolk; Clinical Teacher at University of Cambridge Clinical School of Medicine

Philip Home
Professor of Diabetes Medicine and Consultant Physician in Diabetes and Metabolic Medicine, Newcastle Primary Care Trust

Philip Ivory
Patient/carer representative

Yvonne Johns
Patient/carer representative
Ian Lewin  
Consultant Physician with an interest in diabetes/endocrinology, North Devon District Hospital  

Alistair McGuire  
Head of Social Policy, London School of Economics  

Julie Wood  
Diabetes Nurse Specialist, Diabetes and Renal Programme Manager, Kirklees Primary Care Trust  
The following people were not full members of the GDG but were co-opted onto the group as expert advisers:  

Anthony Barnett  
Professor of Medicine, University of Birmingham and Heart of England NHS Foundation Trust  

Andrew Krentz  
Consultant in Diabetes and Endocrinology, Southampton University Hospitals  
The following individual contributed expertise:  

Alistair Gray  
Director of the Health Economics Research Centre, Division of Public Health and Primary Care, University of Oxford  
The Short Clinical Guidelines Technical Team was responsible for this guideline throughout its development. It was responsible for preparing information for the GDG, for drafting the guideline and for responding to consultation comments. The following people, who are employees of NICE, made up the technical team working on this guideline.  

Tim Stokes  
Associate Director  

Beth Shaw  
Technical Adviser  

Francis Ruiz  
Technical Adviser in Health Economics  

Michael Heath  
Project Manager  

Lynda Ayiku  
Information Specialist  

A.1.3 Guideline development group for 2008 (NICE clinical guideline 66)  

Professor Jonathan Mant (Chair)  
Professor of Primary Care Stroke Research, University of Birmingham
Mrs Lina Bakhshi  
Information Scientist, NCC-CC

Mrs Margaret Bannister  
Nurse Consultant in Diabetes Care, Bradford and Airedale Primary Care Trust

Mrs Katherine Cullen  
Health Economist, NCC-CC

Professor Melanie Davies  
Professor of Diabetes Medicine, University of Leicester

Dr Jose Diaz  
Health Services Research Fellow in Guideline Development, NCC-CC

Mrs Barbara Elster  
Patient and Carer Representative, Essex

Dr Roger Gadsby  
General Practitioner and Senior Lecturer in Primary Care, Warwickshire

Dr Anupam Garrib  
Health Services Research Fellow, NCC-CC

Ms Irene Gummerson  
Primary Care Pharmacist, Yorkshire

Dr Martin Hadley-Brown  
General Practitioner Trainer, University of Cambridge

Professor Philip Home  
Clinical Advisor to the GDG; Professor of Diabetes Medicine, Newcastle University

Mrs Kathryn Leivesley  
Practice Nurse, North Manchester Primary Care Trust

Mrs Emma Marcus  
Clinical Specialist Diabetes Dietitian, Hinckley and Bosworth Primary Care Trust

Mr Leo Nherera  
Health Economist, National Collaborating Centre for Women’s and Children’s Health

Ms Roberta Richey  
Health Services Research Fellow in Guideline Development, NCC-CC

Mr John Roberts  
Patient and Carer Representative, Merseyside

Dr Mark Savage  
Consultant Physician, North Manchester General Hospital
Lorraine Shaw
Paediatric Diabetes Clinical Nurse Specialist, Birmingham Children’s Hospital

Dr Stuart Smelie
Consultant Chemical Pathologist, Bishop Auckland General Hospital

Ms Nicole Stack
Guideline Development Project Manager, NCC-CC

Ms Claire Turner
Guideline Development Senior Project Manager, NCC-CC

Ms Susan Varney
Health Services Research Fellow in Guideline Development, NCC-CC

Dr Jiten Vora
Consultant Physician Endocrinologist, Royal Liverpool and Broadgreen University Hospital

The following experts were invited to attend specific meetings and to advise the Guideline Development Group:

Dr Julian Barth
Consultant Chemical Pathologist, Leeds NHS Trust attended one meeting as a deputy for Dr Stuart Smellie

Dr Indranil Dasgupta
Consultant Physician and Nephrologist, Birmingham Heartlands Hospital

Dr Michael Feher
Consultant Physician, Chelsea Westminster Hospital attended one meeting as a deputy for Dr Mark Savage

Dr Charles Fox
Consultant Physician, Northampton General Trust attended one meeting as a deputy for Professor Melanie Davies

Natasha Jacques
Principal Pharmacist Medicine, Solihull Hospital attended one meeting as a deputy for Ms Irene Gummerson

Dr Eric Kilpatrick
Consultant Chemical Pathologist, University of Hull attended one meeting as a deputy for Dr Stuart Smellie

Dr Ian Lawrence
Consultant Diabetologist, University of Leicester attended one meeting as a deputy for Professor Melanie Davies and Dr Jiten Vora

Professor Sally Marshall
Professor of Diabetes, Newcastle University
Professor David Wood
Professor of Cardiovascular Medicine, Imperial College London

CG66 Acknowledgements

The Guideline Development Group (GDG) is grateful to Bernard Higgins, Jane Ingham, Rob Grant, Jill Parnham and Susan Tann of the NCC-CC for their support throughout the development of the guideline.

The GDG would like to thank the following individuals for giving their time to advise us regarding the design and interpretation of the economic model of analysis of third-line therapy with insulins, glitazones or exenatide in Type 2 diabetes:

- Professor Alastair Gray, University of Oxford
- Dr Philip Clarke, University of Sydney
- Dr Joanne Lord, National Institute for Health and Clinical Excellence.

The GDG would like to thank the following individuals for peer reviewing the guideline:

- Professor Simon Heller, University of Sheffield
- Professor David Owens, Llandough Hospital, Penarth
- Professor Bryan Williams, University of Leicester
- Dr Miles Fisher, Glasgow Royal Infirmary
- Professor Soloman Tesfaye, University of Sheffield
- Mr Irvine Turner, Patient Representative.
# A.2 Declarations of interests

## A.2.1 Declarations of interest for 2015

<table>
<thead>
<tr>
<th>GDG Member</th>
<th>Interest Declared</th>
<th>Declared when?</th>
<th>Type of Interest</th>
<th>Decisions Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amanda Adler - Diabetologist</td>
<td>None declared</td>
<td>July 2012</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Christine Bundy</td>
<td>Holds a Scientific Advisory Board position with Simple Healthcare Products for which an honorarium is received for attending approximately three meetings per year.</td>
<td>July 2012</td>
<td>Non-specific personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Maria Cowell – Community Diabetes Nurse Specialist</td>
<td>None declared</td>
<td>August 2012</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Indranil Dasgrupta (co-opted expert nephrologist)</td>
<td>Has been a member of an advisory board on a new phosphate binder for chronic kidney disease for Mitsubishi Pharma</td>
<td>June 2013</td>
<td>Non-specific personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Indranil Dasgrupta (co-opted expert nephrologist)</td>
<td>Indranil Dasgrupta (co-opted expert nephrologist)</td>
<td>June 2013</td>
<td>Non-specific, non-personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>David Edwards</td>
<td>Acts as a Chair and member on a number of advisory boards. Has organised, chaired and presented at local, national and international meetings on male and/ or female sexual problems and stress. Has written guidelines, been filmed, reviewed/ written articles for both lay and medical press. These activities have been reimbursed by organisations including pharmaceutical companies in the form of transport, accommodation and sometimes honoraria. Companies that travel, accommodation and honoraria have been received from are</td>
<td>July 2013</td>
<td>Non-specific personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Name</td>
<td>Position and Expertise</td>
<td>Conflict of Interest</td>
<td>Declare and</td>
<td>Participate</td>
</tr>
<tr>
<td>------</td>
<td>------------------------</td>
<td>---------------------</td>
<td>-------------</td>
<td>------------</td>
</tr>
<tr>
<td>David Edwards</td>
<td>President of the British Society for Sexual Medicine, Member of Men’s Health Expert Policy Group which aims to educate those in power especially Government and key stakeholders. Travel/occasional accommodation but not time is paid for by Bayer.</td>
<td>Non-specific personal pecuniary interest</td>
<td>Declare and participate</td>
<td></td>
</tr>
<tr>
<td>David Edwards</td>
<td>Clinical advisor to the Klinefelter’s National Association. Member of an advisory board for prostate cancer management known as atypical small acinar proliferation (ASAP).</td>
<td>Non-specific personal pecuniary interest</td>
<td>Declare and participate</td>
<td></td>
</tr>
</tbody>
</table>

Bayer, Eli Lilly, Schwabe and Takeda & Menarini, Pfizer, ProStrakan and Owen Mumford.
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Date</th>
<th>Interest Type</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction)</td>
<td>Participated as a medical researcher for studies undertaken by the Universities of Oxford and Southampton.</td>
<td>July 2013</td>
<td>Non-specific personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>David Edwards (co-opted expert GP with a specialist interest in sexual dysfunction)</td>
<td>Chief investigator in the UK for a study on low dose aspirin. The study is sponsored by Bayer.</td>
<td>July 2013</td>
<td>Non-specific personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Andrew Farmer – GP with a special interest in diabetes (joined the GDG on 7/11/2013)</td>
<td>None declared</td>
<td>November 2013</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Name &amp; Role</td>
<td>Conflict of Interest</td>
<td>Date</td>
<td>Type of Interest</td>
<td>Note</td>
</tr>
<tr>
<td>-------------</td>
<td>---------------------</td>
<td>------</td>
<td>-----------------</td>
<td>------</td>
</tr>
<tr>
<td>Anne Bentley – Primary Care Pharmacist</td>
<td>None declared</td>
<td>July 2012</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Natasha Jacques – Secondary Care Pharmacist</td>
<td>Participation in advisory board on Management of Diabetes in Renal Disease (sponsored by Boehringer Ingelheim) 17.01.12</td>
<td>August 2012</td>
<td>Specific personal pecuniary interest</td>
<td>Declare and participate as in line with NICE policy, it is greater than one year since the conflict occurred and the topics this may relate to are discussed</td>
</tr>
<tr>
<td>Natasha Jacques – Secondary Care Pharmacist</td>
<td>Speaker on ‘Adherence Issues in Diabetes’ - event sponsored by MSD 25.04.12</td>
<td>August 2012</td>
<td>Specific personal pecuniary interest</td>
<td>Declare and participate as in line with NICE policy, it is greater than one year since the conflict occurred and the topics this may relate to are discussed</td>
</tr>
<tr>
<td>Yvonne Johns – patient/carer member</td>
<td>Has been asked by Diabetes UK Wales on behalf of the Welsh Medical Council to discuss and bring forward patient views on lixisenatide for the diabetes group in which she is involved. None of the patients have been asked to use the drug but were asked whether they would consider using it based on an information leaflet they received and their experiences of other GLP1’s</td>
<td>Sept 2013</td>
<td>Personal non-pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Ian Lewin - Diabetologist</td>
<td>None declared</td>
<td>April 2012</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Natasha Marsland – patient/carer member</td>
<td>Employed by Diabetes UK</td>
<td>Oct 2012</td>
<td>Non-personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Prunella Neale – Practice nurse</td>
<td>None declared</td>
<td>Oct 2012</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Jonathan Roddick - GP</td>
<td>Member of MSD advisory board for sitagliptin until appointment.</td>
<td>April 2012</td>
<td>Specific personal</td>
<td>Able to participate as recommendations on</td>
</tr>
<tr>
<td>Name</td>
<td>Activity</td>
<td>Date</td>
<td>Interest Type</td>
<td>Declaration Type</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------</td>
<td>------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Mohamed Roshan – GP</td>
<td>Attended a diabetes advisory meeting. Reimbursement paid to the GP practice.</td>
<td>April 2012</td>
<td>Specific non-personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>(August 2012 –</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mohamed Roshan – GP</td>
<td>Developed and chaired meetings for GLP-1 educational program in Leicester as part of Department of Diabetes</td>
<td>October 2013</td>
<td>Personal non-pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>(August 2012 –</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mohamed Roshan – GP</td>
<td>Attends advisory committee on Lixisenatide for Sanofi and will be trained in future as speaker (last attended March 2013). Received reimbursement to cover locum fees and staff time.</td>
<td>October 2013</td>
<td>Specific personal pecuniary interest</td>
<td>Declare and withdraw</td>
</tr>
<tr>
<td>(August 2012 –</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mohamed Roshan – GP</td>
<td>Will attend conference for discussion on saxagliptin and cardiovascular outcomes evidence recently published. Reimbursement from Astra Zeneca</td>
<td>October 2013</td>
<td>Specific personal pecuniary interest</td>
<td>Declare and withdraw</td>
</tr>
<tr>
<td>(August 2012 –</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mohamed Roshan – GP</td>
<td>Will be training as speaker for Bristol Myer Squibb</td>
<td>October 2013</td>
<td>Specific personal pecuniary interest</td>
<td>Declare and withdraw</td>
</tr>
<tr>
<td>(August 2012 –</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mohamed Roshan – GP</td>
<td>Have chaired meeting for Insulin Degludec (Tresiba) in Sept 2013. Locum expenses reimbursed by Novo Nordisk.</td>
<td>October 2013</td>
<td>Specific personal pecuniary interest</td>
<td>Declare and withdraw</td>
</tr>
<tr>
<td>Name</td>
<td>Activity</td>
<td>Date</td>
<td>Interest</td>
<td>Participation</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------</td>
<td>------------------------------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>Sailesh Sankar - Diabetologist</td>
<td>Attended the International Diabetes Federation in 4th December 2011, the travel and subsistence was supported by Boehringer Ingleheim with in the ABPI regulation guidelines.</td>
<td>July 2012</td>
<td>Specific personal pecuniary interest(s)</td>
<td>Able to participate as recommendations on drug treatment in type 2 diabetes were not made until 2014.</td>
</tr>
<tr>
<td>Sailesh Sankar - Diabetologist</td>
<td>Chaired an evening meeting on the 12th of June 2012 for GP educational session supported by Novo nordisk.</td>
<td>July 2012</td>
<td>Specific personal pecuniary interest(s)</td>
<td>Able to participate as recommendations on drug treatment in type 2 diabetes were not made until 2014.</td>
</tr>
<tr>
<td>Sailesh Sankar - Diabetologist</td>
<td>October 2011 - did an evening educational session for GP’s supported by Boehringer Ingleheim.</td>
<td>July 2012</td>
<td>Specific personal pecuniary interest(s)</td>
<td>Able to participate as recommendations on drug treatment in type 2 diabetes were not made until 2014.</td>
</tr>
<tr>
<td>Sailesh Sankar - Diabetologist</td>
<td>Principal Investigator for Roche EXPERT study. The study recruited patient to use an EXPERT bolus advisor blood glucose monitor versus a Nano monitor. This study was in relation to feasibility of use of bolus advisor in patients with Type 1 diabetes. In this study 9</td>
<td>October 2012</td>
<td>Non-personal specific pecuniary interest(s)</td>
<td>Declare and participate</td>
</tr>
</tbody>
</table>
patients were recruited from Feb 2012 onwards and study was completed in October 2012. This study was funded by ROCHE to meet the expenses of the overheads and running of the study at UHCW site. The UHCW Trust has invoiced the company and the funding yet to be received. The exact amount can be confirmed on receipt.

<table>
<thead>
<tr>
<th>Name</th>
<th>Interest declared</th>
<th>Declared when?</th>
<th>Type of interest?</th>
<th>Decisions taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sailesh Sankar - Diabetologist</td>
<td>Research nurse team was also involved in a retrospective data collection for study/audit conducted at UHCW trust in relation to use of INSULINX blood glucose monitoring in patients with Type 1 diabetes. Funding was (£150.00 per patient data collected) was agreed by the trust R and D in relation to this project. This study was funded by ABOTT diabetes care This was done over September to October 2012 period. Approximately 10 patient’s data was collected for this study.</td>
<td>July 2013</td>
<td>Specific non-personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Sailesh Sankar - Diabetologist</td>
<td>Receiving a grant from Novo Nordisk to lead development of an education application for computer and phone devices for clinicians and medical students. The application will covering managing blood glucose levels for people with diabetes on insulin and preventing ketoacidosis. Novo Nordisk produce insulin licensed for us in people with type 1 and type 2 diabetes.</td>
<td>July 2013</td>
<td>Specific non-personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
</tbody>
</table>

**A.2.2 Declarations of interest for 2009 (NICE clinical guideline 87)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Interest declared</th>
<th>Declared when?</th>
<th>Type of interest?</th>
<th>Decisions taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amanda Adler (Chair)</td>
<td>None</td>
<td>February 2008</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Name</td>
<td>Interest declared</td>
<td>Declared when?</td>
<td>Type of interest?</td>
<td>Decisions taken</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>----------------</td>
<td>----------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Philip Home</td>
<td>Lecturing and consultation contracted by Newcastle University:</td>
<td></td>
<td></td>
<td>Declare and participate</td>
</tr>
<tr>
<td></td>
<td>• Novo Nordisk: pre-mix insulin analogues; insulin detemir research</td>
<td>February 2008</td>
<td>Non-personal pecuniary interest</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Sanofi-aventis: insulin glargine consultation; rimonabant consultation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Roche diagnostics: Accu-check self-monitoring equipment lecturing and consultation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Merck MSD: sitagliptin lecturing and consultation Merck Serono: metformin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>consultation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Novartis: vildagliptin consultation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• GlaxoSmithKline: rosiglitazone research; also pipeline products not in the update</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- consultation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Groupe Servier: gliclazide research and consultation; pipeline products</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Eli Lilly: support to International Diabetes Federation only - not product specific</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(they manufacture insulins and exenatide)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Takeda: pioglitazone - support to International Diabetes Federation; also writing</td>
<td></td>
<td></td>
<td>Declare and participate</td>
</tr>
<tr>
<td></td>
<td>support for review I note that all the above have supported the International</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetes Federation on various initiatives (eg evidence-based guidelines) on which</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I have been lead; I will be expected to support the next World Diabetes Congress</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>for which I am Programme Committee Chair.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niru Goenka</td>
<td>Research grant awarded by Sanofi-Aventis in January 2007 of £4500 to the department</td>
<td>February 2008</td>
<td>Non-personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td></td>
<td>for studying the prevalence of untreated cardiovascular risk factors in a diabetic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>retinopathy laser clinic.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15/5/2007 “Insulin Glulisine (Apidra) Advisory Board Meeting – attended Sanofi</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>advisory board.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>21/06/08 “Update on local glycaemic guidelines” – speaker at MSD sponsored</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>meeting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>05/09/08 “How to get a consultant’s post” – speaker for local SpR teaching</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>programme with sponsorship provided by Sanofi-Aventis.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>06/09/08 “Management of Dyslipidaemia” – speaker at Shering Plough sponsored</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>meeting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>17/9/07 – 21/9/07 “EASD 2007 in Amsterdam” – I received a travel grant from</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Takeda to attend this meeting.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Interest declared</td>
<td>Declared when?</td>
<td>Type of interest?</td>
<td>Decisions taken</td>
</tr>
<tr>
<td>------</td>
<td>-------------------</td>
<td>----------------</td>
<td>-------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td></td>
<td>The grant paid for economy class flights, accommodation and registration for the meeting. I was not required (and did not) attend any Takeda symposium or meeting at this venue and received no personal payment (flights, accommodation and meeting registration were arranged by Takeda within ABPI guidelines – I did not actually receive any money). 15/11/08 “Novel approaches to hypertension” – I chaired a session at a meeting sponsored by Novartis. 20/11/08 “eGFR and Diabetes in General Practice” – speaker at Shering Plough sponsored meeting. 27/11/08 “Changes in the NHS and how they will affect diabetes care” – speaker at Eli Lilly sponsored meeting. 15/01/08 “Current controversies in Diabetes Care” – speaker at MSD sponsored meeting 24/1/08 “Preparing for the future – how to get a consultants post” – speaker at Manchester Respiratory SpR teaching (event was sponsored by GSK). 11/3/08 “Aliskiren – Regional Advisory Board meeting” – attended Novartis Advisory Board. 13/5/08 “Medicolegal aspects in Diabetes Care” – speaker at Takeda sponsored meeting. 09/7/08 Debate “Should diabetes be managed exclusively in primary care” – speaker at Takeda sponsored meeting. 23/7/08 “How not to get sued in Diabetes Care” – speaker at MSD sponsored meeting. 12/08/08 “Update on local diabetic glycaemic guidelines” – speaker at Eli Lilly sponsored meeting. 07/10/08 “New developments in Diabetes” – speaker at Eli Lilly sponsored meeting. 06/11/08 “Individualising treatment in Diabetes” – speaker at Novartis sponsored meeting. 04/02/09 “GSK Round Table discussion on potential results of RECORD study” – attended GSK regional advisory board meeting</td>
<td></td>
<td></td>
<td>My department has previously received research grants from GSK (more than 12 months ago) and Sanofi-Aventis</td>
</tr>
<tr>
<td>Name</td>
<td>Interest declared</td>
<td>Declared when?</td>
<td>Type of interest?</td>
<td>Decisions taken</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>----------------</td>
<td>-------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Ian Lewin</td>
<td>None</td>
<td>February 2008</td>
<td>Non-personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Andrew Farmer</td>
<td>Oxford University received a fee for my delivering a postgraduate educational seminar at a non-promotional meeting organised by MSD on 18th July 2007. I spoke on the role of Diabetes Research Networks in the NHS for ensuring delivery of research evidence to inform clinical practice. I was a member of an advisory board to review data on inhaled insulin convened by Novo in November 2007, fees were paid to Oxford University. Some payments have been received by the Oxford Radcliffe Hospital from a trial that was completed. These payments were from Eli Lilly and Company.</td>
<td>February 2008</td>
<td>Non-personal pecuniary</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Martin Hadley-</td>
<td>Served on advisory boards relating to</td>
<td>February</td>
<td>Non-personal</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Name</td>
<td>Interest declared</td>
<td>Declared when?</td>
<td>Type of interest?</td>
<td>Decisions taken</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Brown</td>
<td>agents or equipment used in diabetes management for the following companies: Novo Nordisk, Glaxo Smith Kline, Takeda, Roche, Sanofi Aventis, Merck Sharp &amp; Dohme, Pfizer. Spoken at educational meetings sponsored by some or all of the above companies. Advisory meetings 20/07/8 19/4/07 Takeda 27/6/07 Novo Nordisk (International Liaison meeting following American Diabetes Assn meeting) 6/7/07 Glaxo SmithKline 20/7/07 Novartis ‘Round Table’ clinicians discussion. 9/8/07 Astra Zeneca 19/10/07 Merck Sharp &amp; Dohme. 8/11/07 Glaxo SmithKline 30/1/08 Roche Pharmaceuticals 2/4/08 Sanofi Aventis. As a committee member of the Primary Care Diabetes Society, the Society has received sponsorship in the form of unrestricted educational grants from a variety of the pharmaceutical companies named above.</td>
<td>2008</td>
<td>pecuniary</td>
<td></td>
</tr>
<tr>
<td>Tony Doherty</td>
<td>Presently working on a 2 year secondment with Diabetes UK as Service Advisor from my present Community Nurse Specialist post. Secondment commenced 15.01.08.</td>
<td>March 2008</td>
<td>Personal non-pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Julie Wood</td>
<td>None</td>
<td>March 2008</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Claudette Allerdyce</td>
<td>None</td>
<td>February 2008</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Yvonne Johns</td>
<td>None</td>
<td>February 2008</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Philip Ivory</td>
<td>None</td>
<td>March 2008</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Alistair McGuire</td>
<td>Advisory work for GSK but money received by working department</td>
<td>March 2008</td>
<td>Non-personal pecuniary interest</td>
<td>Declare and participate</td>
</tr>
<tr>
<td>Tony Barnett</td>
<td>Regularly advise Industry on new product development for diabetes including remuneration for such advice on Advisory Boards. Received remuneration for lectures at scientific meetings supported by Industry. Specifically, this includes companies involved in developing new products for diabetes including GlaxoSmithKline, Takeda, Eli Lilly, Novartis, Merck Sharp &amp; Dohme, Novo Nordisk, Sanofi-Aventis, Astra Zeneca and Bristol Myers Squibb.</td>
<td>February 2008</td>
<td>Personal pecuniary interest</td>
<td>Decision to appoint as a co-opted expert only due to personal pecuniary interests declared.</td>
</tr>
</tbody>
</table>
### A.3 Declarations of interest for 2006 (NICE clinical guideline 66)

**Mrs Margaret C Bannister** (Signed 22/06/2007)
- Personal pecuniary interest:
  - None
- Personal family interest:
  - Sister employed by Astra Zeneca as sales representative. As a member of their academy she had a weekend in Seville in June, to whom a partner was invited and I attended in this capacity.
- Non-personal pecuniary interest:
  - Any honorariums paid for lectures I deliver are paid directly to my employing PCT in the last 12 months I have been paid for such lectures by:
    - Takeda £150
    - GlaxoSmithKline £150
- Personal non-pecuniary interest:
  - None

**Professor Melanie Davies** (Signed 17/07/2007)
- Personal pecuniary interest:
  - Advisory Board for Eli Lilly (exenatide)
  - Speaker fees for Sanofi-Aventis (insulin glargine)
  - Advisory Board for Novo Nordisk (insulin detemir)
  - Advisory Board for MSD for DPP IV and ezetimibe
- Personal family interest:
  - None
- Non-personal pecuniary interest:
  - Educational research grants from Servier/Pfizer and Novo Nordisk to support departmental research
- Personal non-pecuniary interest:
  - Principal investigator for the DESMOND RCT

**Mrs Barbara Elster** (Signed 18/07/2007)
- Personal pecuniary interest:
  - None
- Personal family interest:

---

<table>
<thead>
<tr>
<th>Name</th>
<th>Interest declared</th>
<th>Declared when?</th>
<th>Type of interest?</th>
<th>Decisions taken</th>
<th>Type of Interest?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Krentz</td>
<td>I have received competitive grants for research from the relevant companies</td>
<td>February 2008</td>
<td>Non-personal pecuniary interest</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>mentioned below: GlaxoSmithKline, Takeda, Eli Lilly, Novartis, Merck Sharp &amp; Dohme, Novo Nordisk, Sanofi-Aventis, Astra Zeneca and Bristol Myers Squibb.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
• None
Non-personal pecuniary interest:
• None
Personal non-pecuniary interest:
• None

Dr Roger Gadsby (Signed 17/07/2007)
Personal pecuniary interest:
• Member of Advisory Board for Novo Nordisk, Takeda, Pfizer, MSD and Merck Pharma.
• Speaker at educational events sponsored by Merck Pharma
Personal family interest:
• None
Non-personal pecuniary interest:
• I am Medical Advisor to Warwick Diabetes Care at Warwick Medical School, Warwick University, an organisation which provides diabetes educational programmes across the UK. Several of the courses are supported by unrestricted educational grants from pharma companies. In the past 12 months these have been from Novo Nordisk, Eli Lilly, GSK, Sanofi-Aventis and Lifescan.
I am Honorary Treasurer of the Primary Care Diabetes Society which has received educational grants from GSK, Takeda, Novo Nordisk, Eli Lilly, Sanofi-Aventis, Servier, Roche Diagnostics and Merck Pharma.
Personal non-pecuniary interest:
• None

Ms Irene Gummerson (Signed 20/06/07)
Personal pecuniary interest:
• None
Personal family interest:
• None
Non-personal pecuniary interest:
• None
• Personal non-pecuniary interest:
• None

Dr Martin Hadley-Brown (Signed 17/07/2007)
Personal pecuniary interest:
• Lecture and Advisory Board fees received from GSK, Takeda, Novartis, Novo Nordisk, Astra Zeneca. Only one of these (Novo Nordisk) exceeds £1,000 over the calendar year.
Personal family interest:
• None
Non-personal pecuniary interest:
• None
Personal non-pecuniary interest:
• None

Professor Philip D Home (Signed 21/07/2007)
Personal pecuniary interest:
- Shareholder (medical industries only): NONE
  Other earnings (private practice/other/legal reports) Total under £1,000 p.a.

Personal family interest:
- As a medical writer my wife occasionally has contracts with some of the companies named above.
- She has some funding from IDF and Novo Nordisk projects as above. She has no personal interest otherwise in any medical commercial organisation.
- I have no children under age 18 years.

Non-personal pecuniary interest:
- Continuing intermittent consultation (relates to diabetes/lipid technologies only) for external commercial healthcare organisations (on behalf of University of Newcastle upon Tyne):

Non-personal:
- Sanofi-Aventis, Paris/Guildford
- GlaxoSmithKline plc, Brentford
- Pfizer Inc, New York NY
- Merck Inc, Whitehouse Station NJ
- Sante, Paris
- Novo Nordisk A/S, Copenhagen / Crawley
- Novartis, Basel
- Researche Groupe Servier, Paris
- Roche Diagnostics, Mannheim.

Other consultation for commercial organisations in last 12 months:
- UK and US financial, banking, conference, management consultancy, and support companies (when not knowingly commissioned by named pharmaceutical/diagnostic healthcare companies)
- Research/project grant support to hospital or university:
- Novo Nordisk A/S (discussions with Merck MSD UK, Pfizer UK) International Diabetes Federation:
  - The IDF receives funding from all the above companies except Novartis but also Eli Lilly and Co, Takeda and Merck Sante for activities (Clinical Guidelines Task Force) in which I am involved but not remunerated for. If I change responsibilities at IDF this may extend to all concerns in the diabetes healthcare area.

Directorships:
- North East Diabetes Trust (charity) Diabetes Network International (charity)
- WorldWIDE Initiative for Diabetes Education (non-profit company)
- WorldWIDE is supported by GlaxoSmithKline, Merck Inc, Novartis, Pfizer and Sanofi-Aventis

Personal non-pecuniary interest:
- None

Mrs Emma Marcus (Form signed 25/06/2007)
Personal pecuniary interest:
- None
Personal family interest:
• None
Non-personal pecuniary interest:
• None
Personal non-pecuniary interest:
• None

**Professor Jonathan Mant** (Form signed 18/07/2007)
Personal pecuniary interest:
Consulting for:
• Expert-24 (Norwich Union website)
• PharmaSwiss (company that markets drugs in ex-Yugoslavia)

Personal family interest:
• Brother works for Quintiles (Biotech company)

Non-personal pecuniary interest:
• None

Personal non-pecuniary interest:
• None

**Mr John Roberts** (Form signed 18/07/2007)
Personal pecuniary interest:
• None

Personal family interest:
• None

Non-personal pecuniary interest:
• None

Personal non-pecuniary interest:
• None

**Dr Mark Savage**
Personal pecuniary interest:
• Honoraria received for educational talks to GP/nurses from GSK, Takeda, Lilly, Novartis and Novo-Nordisk

Personal family interest:
• None

Non-personal pecuniary interest:
• None

Personal non-pecuniary interest:
• None

**Dr Stuart Smellie** (Form signed 18/07/2007)
Personal pecuniary interest:
• Occasional lecturing for Merck, Astra-Zeneca and MSD on lipid lowering and advisor in occasional advertising boards

Personal family interest:
• None

Non-personal pecuniary interest:
• None
Personal non-pecuniary interest:
• None

Dr Vora Jiten (Form signed 18/07/2007)
Personal pecuniary interest:
• As previously declared:
• Previous lecturing fees, honoraria for educational meetings from/for: GSK, Takeda, NovoNordisk, Lilly, Sanofi-Aventis, MSD, Novartis

Personal family interest:
• None
Non-personal pecuniary interest:
• None
Personal non-pecuniary interest:
• None